Human papilloma virus(HPV)-associated oropharyngeal cancer(OPC)is a unique entity with increased respon-siveness to treatment and excellent oncologic outcomes.The purpose of this narrative review is to highlight how a...Human papilloma virus(HPV)-associated oropharyngeal cancer(OPC)is a unique entity with increased respon-siveness to treatment and excellent oncologic outcomes.The purpose of this narrative review is to highlight how an improved prognosis for HPV(+)tumors and an ever-increasing understanding of the risk factors,risk stratification,and areas of potential spread are shaping management options.Additionally,we aim to detail how advances in treatment technology on both the surgical and radiation fronts are facilitating the delivery of increas-ingly personalized and precise treatments.This review will describe key aspects of recent and currently-ongoing trials investigating the de-escalation and individualization of treatment in this patient cohort,and how they are building a foundation for distinct treatment paradigms for HPV(+)tumors.Further studies into the integration of biomarker-guided treatments combined with clinical trial enrollment will help ensure a future of personalized treatments and improved outcomes,both in terms of oncologic outcomes and toxicity,for patients with HPV(+)OPC.展开更多
文摘Human papilloma virus(HPV)-associated oropharyngeal cancer(OPC)is a unique entity with increased respon-siveness to treatment and excellent oncologic outcomes.The purpose of this narrative review is to highlight how an improved prognosis for HPV(+)tumors and an ever-increasing understanding of the risk factors,risk stratification,and areas of potential spread are shaping management options.Additionally,we aim to detail how advances in treatment technology on both the surgical and radiation fronts are facilitating the delivery of increas-ingly personalized and precise treatments.This review will describe key aspects of recent and currently-ongoing trials investigating the de-escalation and individualization of treatment in this patient cohort,and how they are building a foundation for distinct treatment paradigms for HPV(+)tumors.Further studies into the integration of biomarker-guided treatments combined with clinical trial enrollment will help ensure a future of personalized treatments and improved outcomes,both in terms of oncologic outcomes and toxicity,for patients with HPV(+)OPC.
